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Abstract
Background: Although the effectiveness of group cognitive-behavioral therapy (GCBT) has been studied, evidence is still not sufficient. Objective: The aim 
of the present study is to consider the effectiveness of GCBT with mood disorders and neurotic disorders. Methods: The present study assessed a total of 32 
patients who were classified as F3 (mood disorders) or F4 (neurotic disorders) according to the ICD-10, and who attended GCBT sessions offered at The Tokai 
University Hospital. Depression and mood in these patients were assessed before and after GCBT by using the Center for Epidemiologic Studies Depression 
Scale (CES-D) and the Profile of Mood States (POMS). Results: A comparison of pre- and post-GCBT CES-D scores among all patients as well as within F3 
and F4 groups showed a significant decrease in CES-D scores after GCBT. As for the POMS, a comparison of pre- and post-GCBT scores among all patients 
showed a significant improvement in “vigor” and “confusion” scores after GCBT. Discussion: The present study demonstrated that GCBT can relieve depression 
and improve some mood states. Furthermore, the GCBT sessions offered proved to be effective even when administered to a group of participants consisting 
of both mood disorders and neurotic disorder patients.
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Introduction
In developed countries, such as England and the United States, a 
form of psychotherapy called Cognitive Behavioral Therapy (CBT) 
has well-established efficacy in the treatment of mood and anxiety 
disorders, and is recommended in guidelines for the management of 
these disorders1-3. Furthermore, previous studies carried out overseas 
have demonstrated that group cognitive-behavioral therapy (GCBT) 
is equally effective as one-on-one CBT sessions4,5.
In Japan, National Health Insurance (NHI) points have been 
assigned to the use of CBT in the treatment of mood disorders since 
April 2010. In addition, previous research on the effectiveness of 
CBT in patients with major depressive disorder found that patients 
experienced a drop in depression after 16 sessions of CBT6. In 
actual clinical settings, however, it is not practical for a psychiatrist 
to routinely administer CBT on a one-on-one basis. Some medical 
institutions therefore offer CBT in group settings. Although there 
are several published studies in Japan that address the effectiveness 
of GCBT in the treatment of psychiatric disorders, many of such 
studies focus only on mood disorders (including major depressive 
disorder)7-9. Furthermore, because there are no established criteria 
for GCBT, individual medical facilities create their own protocols 
and programs but the validity of such protocols and programs has 
not yet been verified. Although GCBT could be effective in treating 
not only major depressive disorder but also anxiety disorder and 
bipolar disorder (particularly, bipolar depression)10, no study has yet 
been conducted in Japan to evaluate the effectiveness of GCBT on 
psychiatric disorders other than major depression disorder.
Tokai University Hospital’s outpatient psychiatric department 
has been offering GCBT as part of the day care rehabilitation 
program since September 2008, and has also been administering 
GCBT sessions on outpatient basis to patients with depression and 
anxiety disorders since June 2012. As is the case with many other 
medical institutions in Japan, the GCBT that we offer is based on 
modification of an individual CBT protocol. Ideally, the efficacy of 
such GCBT approaches should be verified by means of well-designed 
randomized controlled trials (RCTs). This, however, is impractical 
in actual clinical circumstances. Thus, we used an open study design 
to retrospectively examine how GCBT can alleviate depression and 
improve mood states based on the results of multiple psychological 
tests administered before and after GCBT.
Subjects and methods
1) GCBT administered during the present study
① Staff members involved in GCBT and their roles
GCBT staff consisted of one psychiatrist and three to four clinical 
psychologists. The lead clinical psychologist acted as facilitator of 
each session, with all the other clinical psychologists supporting and 
recording the work performed by the participants. The psychiatrist 
educated the participants about depressive and anxiety disorders 
symptoms and treatment from the psychological point of view 
during the first session, and collaborated afterwards with the clinical 
psychologists in providing the necessary support to the participants.
② Inclusion criteria for GCBT
Only the patients who routinely visited our outpatient psychiatric 
department for treatment and satisfied all of the following conditions 
were included in the present study:
• The patient is classified as F3 (mood disorders) or F4 (neu-
rotic disorders) according to the International Statistical 
Classification of Diseases and Related Health Problems, 10th 
revision (ICD-10);
• The patient maintains a regular daily rhythm and is able to 
participate in eight GCBT sessions held once a week;
• The patient has presented good medication adherence;
• The patient has pledged to protect the personal information 
of other participants whom he/she will be encountering 
during the sessions;
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• The patient has agreed to take psychological tests before and 
after the course of therapy sessions, and to attend interviews 
during which he/she will be given feedback on the test results;
• The patient can work on and complete the assignments given 
to them during as well as between sessions;
• The patient is not at risk of self-harm or causing harm to 
others.
Patients were classified according to the primary diagnosis made 
at the time of enrollment in the study. This diagnosis, which was 
made by the psychiatrist with over five years of clinical experience, 
was based on the ICD-10 classification system provided by the World 
Health Organization (WHO). Patients having bipolar disorder and 
exhibiting no signs of mania were included in the F3 group because 
a previous study has demonstrated that CBT is also effective in 
preventing the recurrence of bipolar depression in patients with 
bipolar disorder10.
③ Overview of GCBT
Figure 1 provides an overview of GCBT. Our GCBT protocol/
program is based on the individual CBT protocol developed by 
the Ministry of Health, Labor and Welfare in 2009. According to 
a previous study, a GCBT program generally consists of 8 to 69 
hours of sessions conducted over a period of 5 weeks to 9 months4. 
Taking into consideration the factors associated with the financial 
situation and treatment period of the participants, we developed 
a GCBT program consisting of 8 sessions (a total of 12 hours). 
Because GCBT is administered to a closed group, no new members 
are admitted even when a group member drops out of the therapy. 
The GCBT we used in the present study was unique in that patients 
with mood disorders and those with neurotic disorders received a 
course of GCBT together as a group, instead of being divided into 
different groups by type of disorders. During the two-day period both 
before and after the course of treatment, the participants received 
several different psychological tests. After the tests, they attended 
interviews during which they were given feedback on test results. 
In addition, during the feedback interviews conducted before the 
course of GCBT, GCBT staff members reminded the participants of 
the purpose of participating in GCBT. During the feedback interviews 
conducted after the course of GCBT, staff members compared the 
test results before and after the course of GCBT and discussed with 
the participants their future goals of therapy. An overview of each 
session is provided below.
Introductory session (session 1): Psychological education
The psychiatrist gave a lecture on the symptoms and treatment 
of depression and anxiety disorders. Afterwards, the lead clinical 
psychologist explained the cognitive model to the participants. 
Specifically, he briefed the participants about the seven types of 
automatic thoughts and asked the participants to reflect on their 
patterns of automatic thoughts.
Earlier sessions (sessions 2 to 5): Cognitive restructuring
In sessions 2 and 3, a cognitive model was introduced, where the 
participants summarized the thoughts, emotions, somatic reactions, 
and immediate behaviors associated with their past experiences. 
Furthermore, we evaluated whether any thoughts associated with past 
events fit the description of the seven automatic thoughts discussed 
in session 1, and how such thoughts were correlated with emotions.
In sessions 4 and 5, we provided a detailed description of cognitive 
restructuring. In addition, we used the thought record11 in our attempts 
to encourage participants to restructure past events cognitively.
Later sessions (sessions 6 to 8): Behavioral activation and 
assertion
In session 6, we explained and helped patients develop an action plan 
for behavioral activation. During this session, the participants listed 
the activities that they wished to undertake every day during the next 
week and discussed what they could do to achieve their goals. As 
an assignment to be completed by the next session, the participants 
were asked to actually undertake the listed activities. In session 7, we 
Figure 1. Overview of group cognitive-behavioral therapy.
Administer psychological tests before the course of GCBT sessions.
Conduct interviews to provide feedback on test results.
[Introductory sessions]
[Earlier sessions]
[Later sessions]
1. Educate the participants about depression.
 Provide an overview of cognitive-behavioral therapy (cognitive model).
 Review the seven types of automatic thoughts.
Start a course of therapy sessions (eight 1.5-hour therapy sessions held once a week).
Administer psychological tests after the course of GCBT sessions.
Conduct interviews to provide feedback on test results.
2. Participants sort out their feelings about past experiences by using a cognitive model.
3. Participants sort out their feelings about past experiences by using a cognitive model.
4. Participants reect on their past experiences by using a cognitive restructuring technique.
5. Participants reect on their past experiences by using a cognitive restructuring technique.
6. Participants use the action plan for behavioral activation.
7. Participants use the action plan for behavioral activation.
 Participants receive assertion training.
8. Participants receive assertion training.
 Participants reect on the entire course of the therapy
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reviewed and reflected on the created action plans and explained the 
details about assertion training. In session 8, the participants engaged 
in a role play of assertive behavior based on their past experiences. 
Then, the participants reflected on the entire course of the therapy.
2) Effectiveness of GCBT
There were 35 participants aged 18-62 years who not only met the 
inclusion criteria but also participated in GCBT during the period 
from June 5, 2012 to October 21, 2014. None of the participants with 
mood disorder exhibited psychotic features or had personality disorder. 
Three participants who dropped out of the study during one of the 
sessions were excluded from the analysis. Of these participants, 32 who 
attended all the sessions and who were also able to take the tests before 
and after the course of therapy sessions were included in the analyses.
Depression was evaluated as a primary outcome because, 
generally speaking, anxiety disorder patients no longer exhibit 
pathological anxiety by the time they are well enough to participate 
in the GCBT. The Center for Epidemiologic Studies Depression Scale 
(CES-D), which is accepted worldwide as a highly useful depression 
screening instrument, was used for the evaluation of depression. 
Furthermore, because some of the GCBT participants had anxiety 
disorder or bipolar disorder, the Profile of Mood Status (POMS) was 
used to measure mood state other than depression.
CES-D was used to measure depressive symptomatology. The 
CES-D is a questionnaire used to measure depressive symptoms 
experienced in the past week, consisting of 20 statements (e.g., 
“I was bothered by things that usually don’t bother me”, “My sleep 
was restless”, etc.). The answers to each statement are given on a four-
point rating scale: “none of the time”, “1-2 days”, “3-4 days”, “5-7 days”. 
A cut-off point of 15/16 is used, with higher scores indicating greater 
symptoms of depression. In addition, the Profile of Mood Status 
(POMS) was used in a questionnaire survey that was carried out to 
assess the patients’ mood states. The POMS is a questionnaire that 
contains 65 words/statements that describe feelings people have had 
during the past week. It assesses 6 mood subscales: “tension-anxiety 
(T-A)”, “depression-dejection (D)”, “anger-hostility (A-H)”, “vigor 
(V)”, “fatigue (F)”, and “confusion (C)”. Respondents rate themselves 
on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The cut-
off point is 59/60 for all POMS subscales except “V”, and 39/40 for “V”.
The neuropsychiatric medication taken per day was calculated 
based on the equivalent of a standard medication: for antipsychotic 
medications, chlorpromazine was used as basis for calculation; for 
antidepressant, imipramine hydrochloride was used; for anxiolytics, 
diazepam was used12. Both surveys and neuropsychiatric medication 
were carried out before and after the course of GCBT sessions, as 
summarized in Figure 1. The pre-GCBT and post-GCBT scores from 
these surveys were compared to verify the effectiveness of GCBT.
3) Data analysis
Statistical analyses were performed. A Wilcoxon signed-rank test 
was used to compare pre-GCBT and post-GCBT CES-D and POMS 
scores, and a Mann-Whitney U test was used to compare the test 
results among patients with different diagnoses. SPSS Statistics 
version 14.0 was used for these analyses.
The ethical aspects of the present study were reviewed and 
approved by the Institutional Review Board for Clinical Research, 
Tokai University.
Results
1) Case profile
Table 1 summarizes the baseline profiles of all cases. A total of 32 cases 
were included in the analyses, consisting of 18 male and 14 female 
patients, with the average age being 37.2 (SD = 12.4). Based on the 
ICD-10, 18 of them were diagnosed by the psychiatrist as having 
mood disorders (F30-F39) (hereafter referred to as F3 group), and 
14 of them were diagnosed as having neurotic disorders (F40-F48) 
(hereafter referred to as F4 group).
2) CES-D
Twenty-eight out of 32 participants scored higher than the cut-off 
point pre-GCBT and 20 scored higher than the cut-off post-GCBT. 
The comparison of pre-GCBT and post-GCBT CES-D scores of all 
32 cases by means of Wilcoxon signed-rank test revealed significantly 
lower CES-D scores after the therapy, thus indicating that GCBT may 
be effective in alleviating depression (Z = 4.14, p < 0.01, r = 0.732). 
Similar findings were obtained even when the same comparison was 
made within F3 and F4 groups (F3: Z = -3.25, p < 0.01, r = 0.770, F4: 
Z = -2.54, p < 0.01, r = 0.688) (Table 2.1).
3) POMS
A Wilcoxon signed-rank test was used to compare pre-GCBT and 
post-GCBT POMS scores. Patients scored significantly higher on the 
“vigor” (V) subscale and exhibited increased levels of vitality after 
GCBT (Z = -2.01, p < 0.05). Furthermore, patients scored significantly 
lower on the “confusion” (C) subscale after GCBT, and they actually 
became less confused and were able to make decisions with greater 
ease (Z = -2.17, p < 0.05). However, when the same comparison 
was made within F3 and F4 groups, no significant differences were 
observed on any of the POMS subscales (Table 2.1).
The comparison of pre-GCBT CES-D and POMS scores between 
F3 and F4 groups revealed no significant differences on any of either 
the CES-D items or POMS subscales. Similarly, the comparison of post 
GCBT test scores between F3 and F4 groups revealed no significant 
differences on any of either the CES-D items or POMS subscales.
Table 1. Profile of participants (n = 32)
Average age (S.D.) 37.2 (±12.4)
F/M 14/18
ICD-10 F3 F30 0
F31 2
F32 9
F33 3
F34 4
F38 0
F39 0
F4 F40 3
F41 6
F42 1
F43 3
F44 0
F45 1
F48 0
4) Neuropsychiatric medication
There was no significant difference in the amount of neuropsychiatric 
medication taken per day in either group (Table 2.2).
Discussion
Although several studies have focused on the effectiveness of GCBT 
in alleviating depression, only a few studies have addressed how 
GCBT might help patients in other mood states. In the present study, 
we examined whether GCBT can alleviate depression and improve 
mood states by using the CES-D and the POMS, respectively. As a 
result, we  found a significant decrease in the depression scores 
calculated by using the CES-D after GCBT,  observed a significant 
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Table 2.1. Comparison of CES-D/POMS score between pre- and post-CBT
Total (n = 32) F3 (n = 18) F4 (n = 14)
Pre-CBT (SD) Post-CBT (SD) Z Effect 
size (r)
Pre-CBT 
a) (SD 
values)
Post-
CBT  
b) (SD 
values)
a) vs b) Z Effect 
size (r)
Pre-CBT 
c) (SD 
values)
Post-
CBT 
d) (SD 
values)
c) vs d) Z Effect 
size 
(r)
a) vs 
c) Z  
Effect 
size 
(r)
b) vs 
d) Z
Effect 
size 
(r)
CES-D 25.97 (10.55) 20.25 (10.01) -4.14** 0.732 25.83 20.39 -3.25** 0.770 26.14 20.07 -2.54** 0.688 0.02 0.000 0.32 0.001
POMS T-A 60.43 (12.36) 57.72 (13.87) -1.29 0.229 60.44 56.89 -1.07 0.257 60.43 58.79 -0.56 0.148 0.10 0.000 0.15 0.001
D 66.72 (13.52) 64.22 (13.13) -1.40 0.248 67.89 63.83 -1.94 0.402 65.21 64.71 -0.04 0.000 0.53 0.002 0.25 0.001
A-H 51.25 (12.87) 52.84 (14.32) -0.53 0.096 51.22 53.06 -0.83 0.201 51.29 52.57 -0.04 0.019 0.06 0.000 0.29 0.001
V 37.34 (6.05) 40.22 (8.02) -2.01* 0.357 37.56 40.72 -1.76 0.420 37.07 39.57 -0.71 0.202 0.17 0.001 1.07 0.004
F 61.34 (12.74) 59.53 (13.72) -1.01 0.18 61.67 60.61 -0.23 0.061 60.93 58.14 -1.61 0.436 0.29 0.001 0.53 0.002
C 63.75 (14.01) 59.53 (11.35) -2.17* 0.385 63.94 58.78 -1.89 0.451 63.50 60.50 -1.02 0.285 0.08 0.000 0.32 0.001
CES-D: The Center for Epidemiologic Studies Depression Scale.
POMS: The Profile of Mood Status.
T-A: Tension – Anxiety; D: Depression – Dejection; A-H: Anger – Hostility; V: Vigor; F: Fatigue; C: Confusion.
Total, a) vs b), and c) vs d) : Wilcoxon signed-rank test.
a) vs c) and b) vs d) : Mann-Whitney U test.
Effect size (r) depends on correlation coeficient.
** p < 0.01 * p < 0.05.
Table 2.2. Comparison of the usage of neuropsychiatric medication between pre- and post-CBT
Total F3 F4
n Pre-
CBT 
(SD)
Post-
CBT 
(SD)
Z Effect 
size (r)
n Pre-
CBT 
(SD)
Post-
CBT 
(SD)
Z Effect 
size (r)
n Pre-
CBT 
(SD)
Post-
CBT 
(SD)
Z Effect 
size (r)
Antidepressannt  
(imipramine equivalent, mg/day)
21 123.2
 (95.27)
98.8
 (84.01)
1.29 0.282 12 100.0
 (58.77)
101.0
 (106.1)
0.67 0.195 9 154.2 
(126.71)
95.8
 (46.35)
1.35 0.451 
Anxiolytics  
(diazepam equivalent, mg/day)
20 14.1
 (12.39)
15.6
 (19.93)
0.02 0.006 9 17.9
 (16.87)
22.7
 (27.13)
0.51 0.169 11 11.0
(6.30)
9.8
 (9.11)
0.65 0.196 
Antipsychotic  
(chlorpromazine equivalent, mg/day)
- - - - 4 156.4 
(200.29)
50.2
 (99.88)
0.44 0.183 - - - - -
Total, F3, F4: Wilcoxon signed-rank test effect size (r) depends on correlation coefficient.
increase in the “vigor” subscale scores and a significant decrease in 
the “confusion” subscale scores on the POMS after GCBT, and  
confirmed that these effects (those mentioned in  and  above) 
can be produced even among a group of participants including not 
only mood disorder patients (F3) but also neurotic disorder patients 
(F4) who have been diagnosed by using the ICD-10.
These findings, along with similar results published overseas4,5 
as well as in Japan7-9, suggest that GCBT could also be effective in 
alleviating depression. CBT is believed to be effective for patients 
with depression because it involves interventions aimed at addressing 
negative automatic thoughts that lead to depression. In fact, Mukhtar 
and Nishimura have reported negative automatic thoughts to be one 
of the predictor variables that is associated with the effectiveness 
of GCBT in alleviating depression13,14. In our GCBT sessions, we 
focused on replacing negative automatic thoughts with more adaptive 
thoughts by using a cognitive restructuring technique which is 
believed to have contributed to the relief of depression.
There are no studies that evaluated GCBT in patients with major 
depressive disorder or anxiety disorder and evaluated their effects 
using POMS.
An improvement in the “vigor” subscale scores after GCBT can be 
attributed to two reasons:  reflecting on past experiences through 
cognitive restructuring helps alleviate the participants’ psychological 
burden, and  preparing and implementing an action plan help 
improve motivation and activeness in participants. A decrease in 
the “confusion” subscale scores after GCBT can also be attributed 
to two reasons:  exchanging ideas within group members helps 
each member discover feelings that he or she had not been aware of 
before, and  participants are able to sort out their feelings within 
a specific framework by using a cognitive restructuring technique. 
The same comparison (i.e. the comparison of pre- and post-GCBT 
“vigor” and “confusion” subscale scores) made within F3 and F4 
groups also revealed similar trends, but the differences were not 
statistically significant. This may be due to the small sample size. 
On the T-A and F subscales, the participants scored higher than the 
cut-off pre- GCBT and lower than the cut-off post- GCBT, although 
no significant differences were found between pre- and post-GCBT 
subscale scores. Although this non-significance may be due to the 
small sample size, it could also suggest the limited effectiveness of 
our GCBT approach. On the other hand, although a significant 
difference was found between pre- and post-GCBT CES-D scores, 
no significant difference was found between pre- and post-GCBT 
“Depression/Anxiety” POMS subscale scores. This may be attributed 
to the fact that CES-D contains some statements that reflect everyday 
aspects of life, including appetite and sleep, which are not addressed 
by the POMS.
While most of the previous studies tested GCBT among only 
those patients diagnosed with mood disorders, the present study 
offered GCBT sessions to a group of participants consisting of not 
only those diagnosed with ICD-10 F3 mood disorders but also 
those diagnosed with ICD-10 F4 neurotic disorders. Interestingly, 
it demonstrated that GCBT is effective in alleviating depression 
and improving mood states even within a group of individuals 
diagnosed with different types of psychiatric disorders. Recently, 
the effectiveness of GCBT by a unified protocol covering both mood 
disorders and anxiety disorders has been reported, however our 
GCBT is simple and fewer than these unified protocols15. Moreover, 
our CBT was effective for both mood disorder and anxiety disorder, 
this finding suggests that our GCBT may be applied to a wider range 
of patients. A previous study reports that witnessing what other 
people say or do help participants gain greater self-insight into their 
own thoughts and behaviors16. Applying GCBT to a wider range of 
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patients can benefit participating patients because they will then have 
a greater chance of encountering someone with similar backgrounds, 
with whom they can share their experience and from whom they can 
seek advice or reassurance.
The present study has, however, some limitations. Firstly, although 
CBT protocols targeting individual patients (such protocols are 
sometimes called “individual CBT protocols”) are well-established 
in Japan, many healthcare providers in Japan are still unfamiliar with 
GCBT protocols. Both in terms of their design and the number of 
sessions held, the GCBT sessions provided in the present study are 
based on modification of an individual CBT protocol. We have not yet 
verified whether our GCBT protocol/program is equally effective as the 
individual CBT. Secondly, because the present study used a retrospective 
design and an open study design, the effects of drug therapy or other 
outpatient treatment and care received by the participants were not 
fully controlled for. Thus, in order to draw definitive conclusions about 
the treatment effect of our GCBT approach, we need to reevaluate 
our approach by using more rigorous research methods like RCTs. 
Thirdly, although the present study included patients belonging to 
the F4 category (i.e., patients with anxiety disorder, etc.), our analysis 
failed to specifically focus on changes in anxiety status. However, the F4 
group on average scored 60.4 points on the T-A subscale of the POMS, 
which was only slightly higher than a cut-off value of 60. Furthermore, 
no difference was observed between the F3 and F4 groups at baseline 
or at the end of GCBT. Fourthly, the follow-up period was not long 
enough either to determine long-term treatment effects of GCBT or 
to assess the possibility of recurrence. Finally the total sample size 
was limited to 32 patients. A larger sample size in future studies may 
render more significant results.
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